Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Hansha Must Deal with Generics from All Companies: Mr Eguchi of Seibu Sawai
February 25, 2008
- FY2008 Revision of Medical Fees Recommended by Chuikyo
February 25, 2008
- Premium of 4 Points to Be Paid to Heavy Generic Dispensers
February 25, 2008
- BUSINESS NEWS IN BRIEF
February 25, 2008
- Generics to Be NHI Price Listed in May and November from FY2009
February 25, 2008
- NHI Pricing Procedures to See Changes
February 25, 2008
- TOPICS／Poster Prepared by Korosho to Promote Use of Generics
February 25, 2008
- JPA Satisfied with Proposed Dispensing Fees: JPA Vice President
February 25, 2008
- Piecework System Should Be Applied to Drugs Used at Nursing Care Facilities
February 25, 2008
- MTX Recommended for Approval for JIA
February 25, 2008
- New System to Cover Certain Unapproved Medical Services by Insurance from April
February 25, 2008
- REGULATORY NEWS IN BRIEF
February 25, 2008
- 600 Points per Month for Managing Health of Elderly Patients
February 25, 2008
- JPMA to Study Clinical Trial Situation in Other Asian Countries
February 25, 2008
- MRI Using EOB Primovist Incorporates All Features of Conventional Methods
February 25, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 25, 2008
- Use of Standard Forms for Clinical Trial Documents
February 25, 2008
- Large-scale Databases Important for ADR Analysis
February 25, 2008
- Objection to Use of Literature by MRs without Obtaining Prior Consent
February 18, 2008
- REGULATORY NEWS IN BRIEF
February 18, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…